COX-2 Safety Concerns Are Affecting Celebrex, Pharmacia Says
Executive Summary
The withdrawal of Bayer's cholesterol agent Baycol may help Pharmacia in its efforts to differentiate Celebrex from Vioxx in the COX-2 inhibitor class, Global Prescription Business President Carrie Cox suggested during the Bear Stearns "virtual" healthcare conference Sept. 26.
You may also be interested in...
Pharmacia Bextra Pre-Launch Will Develop “Real Life Experience” With Drug
Pharmacia will pre-launch Bextra with select physicians to gather "real life experience" in advance of the COX-2 inhibitor's full launch in April
Pharmacia Bextra Pre-Launch Will Develop “Real Life Experience” With Drug
Pharmacia will pre-launch Bextra with select physicians to gather "real life experience" in advance of the COX-2 inhibitor's full launch in April
Medicare Rx Benefit Could Help Ignite COX-2 Market – Pharmacia’s Hassan
A Medicare drug benefit could help jump-start the stalled COX-2 inhibitor market, Pharmacia CEO Fred Hassan told analysts during the company's annual investor day in New York City Nov. 28